{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:05:07Z","timestamp":1771275907212,"version":"3.50.1"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This is a unique case of fulminant respiratory failure secondary to a rare cause of rapidly progressing ILD; antisynthetase syndrome (ASS). Failure to deliver timely multi-modal treatment in these cases can lead to increased morbidity and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A previously healthy 27-year-old male presented to his local hospital with a 1-week history of malaise, shortness of breath and cough. Initial work up including bloods and imaging were suggestive of community acquired multi lobar pneumonia, for which he received treatment as per local guidelines. Unfortunately, despite broad empirical antimicrobial cover, he continued to deteriorate with worsening type-1 respiratory failure requiring intubation and subsequent institution of prone position ventilation. Extensive microbiological investigations yielded no positive results. On day 7 of admission immunological testing revealed an ENA screen positive for Jo-1 antibody and a diagnosis of ASS was made. Despite treatment with immunosuppression the patient\u2019s condition rapidly deteriorated and the decision to support with V-V ECMO was made following MDT consideration as there remained uncertainty as to the extent of reversibility of the underlying condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This patient recovered with combination of conventional immunosuppression, therapeutic plasma exchange and ECMO support. This case highlights Antisynthetase syndrome as a cause of reversible interstitial lung disease in the ICU and the importance of multi-disciplinary decision making and aggressive treatment approach in the management of such conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/jccm-2026-0006","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:03:23Z","timestamp":1771265003000},"page":"110-116","source":"Crossref","is-referenced-by-count":0,"title":["Veno-venous ECMO for rapidly progressing interstitial lung disease: A multidisciplinary approach"],"prefix":"10.2478","volume":"12","author":[{"given":"Samreen","family":"Tariq","sequence":"first","affiliation":[{"name":"Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"O\u2019Hannigan","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizrull","family":"Nasir","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Marsh","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hastings","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Stack","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Kelliher","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026021620181321661_j_jccm-2026-0006_ref_001","doi-asserted-by":"crossref","unstructured":"Witt LJ, Curran JJ, Strek ME. The Diagnosis and Treatment of Antisynthetase Syndrome. Clin Pulm Med. 2016;23(5):218\u201326.","DOI":"10.1097\/CPM.0000000000000171"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_002","doi-asserted-by":"crossref","unstructured":"Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Practice & Research Clinical Rheumatology. 2020;34(4):101503.","DOI":"10.1016\/j.berh.2020.101503"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_003","doi-asserted-by":"crossref","unstructured":"Trudzinski FC, Kaestner F, Sch\u00e4fers HJ, F\u00e4hndrich S, Seiler F, B\u00f6hmer P, et al. Outcome of Patients with Interstitial Lung Disease Treated with Extracorporeal Membrane Oxygenation for Acute Respiratory Failure. Am J Respir Crit Care Med. 2016;193(5):527\u201333.","DOI":"10.1164\/rccm.201508-1701OC"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_004","doi-asserted-by":"crossref","unstructured":"Gu\u00e9rin C, Reignier J, Richard J-C, Beuret P, Gacouin A, Boulain T, et al. Prone Positioning in Severe Acute Respiratory Distress Syndrome. New England Journal of Medicine. 2013;368(23):2159\u201368.","DOI":"10.1056\/NEJMoa1214103"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_005","doi-asserted-by":"crossref","unstructured":"Grasso S, Stripoli T, De Michele M, Bruno F, Moschetta M, Angelelli G, et al. ARDSnet ventilatory protocol and alveolar hyperinflation: role of positive end-expiratory pressure. Am J Respir Crit Care Med. 2007;176(8):761\u20137.","DOI":"10.1164\/rccm.200702-193OC"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_006","doi-asserted-by":"crossref","unstructured":"Papazian L, Forel J-M, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome. New England Journal of Medicine. 2010;363(12):1107\u201316.","DOI":"10.1056\/NEJMoa1005372"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_007","unstructured":"Zanframundo G FKS, Yoshida A, Dourado E, Bauer Ventura I, Rivero Gallegos D, Loganathan A, Sambataro G, Bozan F, Bae S, Lim D, Cheli M, Yamano Y, Bonella F, Corte T, Doyle T, Fiorentino D, Gonzalez-Gay M, Hudson M, Kuwana M, Lundberg I, Mammen A, McHugh N, Miller F, Montecucco C, Oddis C, Rojas-Serrano J, Schmidt J, Scir\u00e8 C, Selva-O\u2019Callaghan A, Werth V, Rozza D, Morosini M, Bozzini S, Cavagna L, Aggarwal R. . The Classification Criteria for Anti-Synthetase Syndrome (Class) Project [abstract] Arthritis Rheumatol. 2024; 76 (suppl 9). 2024 [Available from: https:\/\/acrabstracts.org\/abstract\/the-classification-criteria-for-anti-synthetase-syndrome-class-project\/."},{"key":"2026021620181321661_j_jccm-2026-0006_ref_008","doi-asserted-by":"crossref","unstructured":"Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77(282):1019\u201338.","DOI":"10.1093\/qjmed\/77.1.1019"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_009","doi-asserted-by":"crossref","unstructured":"Yang H, Chen Q, Sun C, Jin Q, Zhang L, Liu Q, et al. Clinical and prognostic associations of anti-Jo-1 antibody levels in patients with antisynthetase syndrome. Respir Res. 2024;25(1):222.","DOI":"10.1186\/s12931-024-02851-w"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_010","doi-asserted-by":"crossref","unstructured":"Sodsri T, Petnak T, Ngamjanyaporn P. Clinical Characteristics of Anti-Synthetase Syndrome and Variables Associated with Interstitial Lung Disease and Mortality: A Retrospective Cohort Study. Journal of Clinical Medicine [Internet]. 2023; 12(21).","DOI":"10.3390\/jcm12216849"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_011","doi-asserted-by":"crossref","unstructured":"Vuillard C, Pineton de Chambrun M, de Prost N, Gu\u00e9rin C, Schmidt M, Dargent A, et al. Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study. Annals of Intensive Care. 2018;8(1):87.","DOI":"10.1186\/s13613-018-0433-3"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_012","doi-asserted-by":"crossref","unstructured":"Kouranloo K, Dey M, Elwell H, Yioe V, Spencer LG, Cotton CV. Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review. Rheumatology. 2025;64(1):45\u201355.","DOI":"10.1093\/rheumatology\/keae403"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_013","doi-asserted-by":"crossref","unstructured":"McAdoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant. 2019;34(1):63\u201373.","DOI":"10.1093\/ndt\/gfx378"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_014","doi-asserted-by":"crossref","unstructured":"Benad M, DK, KH, KW, AK, MA. Effects of cyclophosphamide and rituximab in patients with connective tissue diseases with severe interstitial lung disease. Clinical and Experimental Rheumatology 2022;40:483\u20138.","DOI":"10.55563\/clinexprheumatol\/o5t1f7"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_015","unstructured":"Rheumatology AC. 2023 American College of Rheumatology (ACR) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease Guideline Summary. 2023."},{"key":"2026021620181321661_j_jccm-2026-0006_ref_016","doi-asserted-by":"crossref","unstructured":"Omotoso BA, Ogden MI, Balogun RA. Therapeutic plasma exchange in antisynthetase syndrome with severe interstitial lung disease. J Clin Apher. 2015;30(6):375\u20139.","DOI":"10.1002\/jca.21387"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_017","doi-asserted-by":"crossref","unstructured":"Bozkirli DE, Kozanoglu I, Bozkirli E, Yucel E. Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis. J Clin Apher. 2013;28(6):422\u20135.","DOI":"10.1002\/jca.21285"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_018","doi-asserted-by":"crossref","unstructured":"Eller P, Flick H, Schilcher G, Moazedi-F\u00fcrst F, Eller K, Talakic E, et al. Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series. BMC Pulm Med. 2021;21(1):13.","DOI":"10.1186\/s12890-020-01386-2"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_019","doi-asserted-by":"crossref","unstructured":"Tekkatte R, Yadav P, Venkatachala SK, Dibbur V. A Successful Rescue Therapy with Plasma Exchange for Rapidly Progressive Interstitial lung Disease Associated Antisynthetase Syndrome. Indian Journal of Rheumatology. 2023;18(1).","DOI":"10.4103\/injr.injr_58_21"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_020","unstructured":"Dequeker J, Geusens P, Wielands L. Short and longterm experience with plasmapheresis in connective tissue diseases. Biomedicine. 1980;32(4):189\u201394."},{"key":"2026021620181321661_j_jccm-2026-0006_ref_021","doi-asserted-by":"crossref","unstructured":"Schmidt M, Bailey M, Sheldrake J, Hodgson C, Aubron C, Rycus PT, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. Am J Respir Crit Care Med. 2014;189(11):1374\u201382.","DOI":"10.1164\/rccm.201311-2023OC"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_022","doi-asserted-by":"crossref","unstructured":"Raff LA, Gallaher JR, Johnson D, Raff EJ, Charles AG, Reid TS. Time to Cannulation after ICU Admission Increases Mortality for Patients Requiring Veno-venous ECMO for COVID-19 Associated Acute Respiratory Distress Syndrome. Ann Surg. 2022;276(6):e659\u2013e63.","DOI":"10.1097\/SLA.0000000000004683"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_023","doi-asserted-by":"crossref","unstructured":"Hermann M, Laxar D, Krall C, Hafner C, Herzog O, Kimberger O, et al. Duration of invasive mechanical ventilation prior to extracorporeal membrane oxygenation is not associated with survival in acute respiratory distress syndrome caused by coronavirus disease 2019. Ann Intensive Care. 2022;12(1):6.","DOI":"10.1186\/s13613-022-00980-3"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_024","doi-asserted-by":"crossref","unstructured":"Sampson C, Taylor J, Dyson L, Hassanein M. Life-threatening respiratory failure requiring extra-corporeal membrane oxygenation secondary to the anti-synthetase syndrome. J Intensive Care Soc. 2021;22(1):83\u20137.","DOI":"10.1177\/1751143719840260"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_025","doi-asserted-by":"crossref","unstructured":"Pineton de Chambrun M, Hervier B, Chauveau S, Tandjaoui-Lambiotte Y, Combes A, Uzunhan Y. Tofacitinib in antisynthetase syndrome-related rapidly progressive interstitial lung disease. Rheumatology (Oxford). 2020;59(12):e142\u2013e3.","DOI":"10.1093\/rheumatology\/keaa323"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_026","doi-asserted-by":"crossref","unstructured":"Lio KU, Li S. Anti-synthetase syndrome masquerading as recurrent pneumonia. BMJ Case Rep. 2023;16(6).","DOI":"10.1136\/bcr-2023-255130"},{"key":"2026021620181321661_j_jccm-2026-0006_ref_027","doi-asserted-by":"crossref","unstructured":"Rubin J, Black KE, Hallowell RW, Witkin AS, Lydston M, Shelton K, et al. Veno-Venous Extracorporeal Membrane Oxygenation for Myositis-Associated Rapidly Progressive Interstitial Lung Disease. Chest. 2021;160(6):2163\u20137.","DOI":"10.1016\/j.chest.2021.06.075"}],"container-title":["The Journal of Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciendo.com\/pdf\/10.2478\/jccm-2026-0006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:18:23Z","timestamp":1771273103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.2478\/jccm-2026-0006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["10.2478\/jccm-2026-0006"],"URL":"https:\/\/doi.org\/10.2478\/jccm-2026-0006","relation":{},"ISSN":["2393-1817"],"issn-type":[{"value":"2393-1817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}